Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells

Journal of Muscle Research and Cell Motility

Volumn 27, Issue 1, 2006, Pages 53-67

  Draviam, Romesh A ^a   Wang, Bing ^a   Li, Juan ^a   Xiao, Xiao ^a   Watkins, Simon C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA DYSTROGLYCAN; DYSTROPHIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; LATRUNCULIN A;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; COMPLEX FORMATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MICROSCOPY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RAT; REPORTER GENE; SARCOLEMMA; WILD TYPE;

ACTINS; ACTIVE TRANSPORT, CELL NUCLEUS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; CELL MEMBRANE; DYSTROGLYCANS; DYSTROPHIN; GREEN FLUORESCENT PROTEINS; HUMANS; MACROMOLECULAR SUBSTANCES; MOLECULAR WEIGHT; MUSCLE FIBERS; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SARCOLEMMA; THIAZOLIDINES;

EID: 33745012208     PISSN: 01424319     EISSN: 15732657     Source Type: Journal    
DOI: 10.1007/s10974-006-9055-8     Document Type: Article

References (58)

1. Andre B and Springael JY (1994) WWP, a new amino acid motif present in single or multiple copies in various proteins including dystrophin and the SH3-binding Yes-associated protein YAP65. Biochem Biophys Res Commun 205: 1201-1205.
2. Bachrach E and Li S et al. (2004) Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc Natl Acad Sci USA 101: 3581-3586.
3. Bork P and Sudol M (1994) The WW domain: a signalling site in dystrophin?. Trends Biochem Sci 19: 531-533.
4. Brennan PA and Jing J et al. (2004) Dystroglycan complex in cancer. Eur J Surg Oncol 30: 589-592.
5. Campeau P and Chapdelaine P et al. (2001) Transfection of large plasmids in primary human myoblasts. Gene Ther 8: 1387-1394.
6. Chapdelaine P and Moisset PA et al. (2000) Functional EGFP-dystrophin fusion proteins for gene therapy vector development. Protein Eng 13: 611-615.
7. Chen HI and Sudol M (1995) The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 92: 7819-7823.
8. Chen YJ and Spence HJ et al. (2003) Direct interaction of beta-dystroglycan with F-actin. Biochem J 375: 329-337.
9. Cohn RD and Henry MD et al. (2002) Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110: 639-648.
10. Corrado K and Rafael JA et al. (1996) Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype. J Cell Biol 134: 873-884.
11. Cote PD and Moukhles H et al. (2002) Dystroglycan is not required for localization of dystrophin, syntrophin, and neuronal nitric-oxide synthase at the sarcolemma but regulates integrin alpha 7B expression and caveolin-3 distribution. J Biol Chem 277: 4672-4679.
12. Cox GA and Sunada Y et al. (1994) Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet 8: 333-339.
13. Decrouy A and Renaud JM et al. (1998) Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx4 cv skeletal muscle fibers. Gene Ther 5: 59-64.
14. Draviam R and Billington L et al. (2001) Confocal analysis of the dystrophin protein complex in muscular dystrophy. Muscle Nerve 24: 262-272.
15. Dunckley MG and Wells KE et al. (1994) Independent localization of dystrophin N- and C-terminal regions to the sarcolemma of mdx mouse myofibres in vivo. J Cell Sci 107: 1469-1475.
16. Ehrhardt D (2003) GFP technology for live cell imaging. Curr Opin Plant Biol 6: 622-628.
17. Ellenberg J and Lippincott-Schwartz J et al. (1999) Dual-colour imaging with GFP variants. Trends Cell Biol 9: 52-56.
18. Fabb SA and Wells DJ et al. (2002) Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 11: 733-741.
19. Flanigan KM and von Niederhausern A et al. (2003) Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 72: 931-939.
20. Gussoni E and Blau HM et al. (1997) The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3: 970-977.
21. Hoffman EP and Brown RH Jr. et al. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
22. Hoffman EP and Fischbeck KH et al. (1988) Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 318: 1363-1368.
23. Hoffman EP and Kunkel LM (1989) Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 2: 1019-1029.
24. Huang X and Poy F et al. (2000) Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat Struct Biol 7: 634-638.
25. Ishikawa-Sakurai M and Yoshida M et al. (2004) ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. Hum Mol Genet 13: 693-702.
26. Jung D and Yang B et al. (1995) Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem 270: 27305-27310.
27. Kaplitt MG and Leone P et al. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8: 148-154.
28. Kapsa R and Kornberg AJ et al. (2003) Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2: 299-310.
29. Kay MA and Manno CS et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261.
30. Kessler PD and Podsakoff GM et al. (1996) Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93: 14082-14087.
31. Koenig M and Monaco AP et al. (1988) The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53: 219-226.
32. Kunkel LM (1986) Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322: 73-77.
33. Lenk U and Oexle K et al. (1996) A cysteine 3340 substitution in the dystroglycan-binding domain of dystrophin associated with Duchenne muscular dystrophy, mental retardation and absence of the ERG b-wave. Hum Mol Genet 5: 973-975.
34. Lesage B and Beullens M et al. (2004) Interactor-mediated nuclear translocation and retention of protein phosphatase-1. J Biol Chem 279: 55978-55984.
35. Malhotra SB and Hart KA et al. (1988) Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 242: 755-759.
36. Morton WM and Ayscough KR et al. (2000) Latrunculin alters the actin-monomer subunit interface to prevent polymerization. Nat Cell Biol 2: 376-378.
37. Muzyczka N (1992) Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158: 97-129.
38. Nicholson LV and Johnson MA et al. (1990) Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathol (Berl) 80: 239-250.
39. Norwood FL and Sutherland-Smith AJ et al. (2000) The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure Fold Des 8: 481-491.
40. Ponting CP and Blake DJ et al. (1996) ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Trends Biochem Sci 21: 11-13.
41. Pruchnic R and Cao B et al. (2000) The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther 11: 521-536.
42. Radojevic V and Lin S et al. (2000) Differential expression of dystrophin, utrophin, and dystrophin-associated proteins in human muscle culture. Cell Tissue Res 300: 447-457.
43. Rafael JA and Cox GA et al. (1996) Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 134: 93-102.
44. Royuela M and Chazalette D et al. (2003) Formation of multiple complexes between beta-dystroglycan and dystrophin family products. J Muscle Res Cell Motil 24: 387-397.
45. Rybakova IN and Amann KJ et al. (1996) A new model for the interaction of dystrophin with F-actin. J Cell Biol 135: 661-672.
46. Sakamoto M and Yuasa K et al. (2002) Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 293: 1265-1272.
47. Sastri M, Barraclough DM, et al. (2005). A-kinase-interacting protein localizes protein kinase A in the nucleus." Proc Natl Acad Sci USA.
48. Sgambato A and Brancaccio A (2005) The dystroglycan complex: from biology to cancer. J Cell Physiol.
49. Simons M and Kramer EM et al. (2002) Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J Cell Biol 157: 327-336.
50. Spector I and Shochet NR et al. (1983) Latrunculins: novel marine toxins that disrupt microfilament organization in cultured cells. Science 219: 493-495.
51. Tuffery-Giraud S and Chambert S et al. (1999) Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat 14: 359-368.
52. Wang B and Li J et al. (2000) Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 97: 13714-13719.
53. Watchko J and O'Day T et al. (2002) Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 13: 1451-1460.
54. Watkins SC and Hoffman EP et al. (1988) Immunoelectron microscopic localization of dystrophin in myofibres. Nature 333: 863-866.
55. Wessel HB (1990) Dystrophin: a clinical perspective. Pediatr Neurol 6: 3-12.
56. Williamson RA and Henry MD et al. (1997) Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 6: 831-841.
57. Xiao X and Li J et al. (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098-8108.
58. Xiao X and Li J et al. (2000) Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 74: 1436-1442.